Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A. Munger KL, et al. Among authors: pohl c. Neurology. 2015 Nov 10;85(19):1694-701. doi: 10.1212/WNL.0000000000002099. Epub 2015 Oct 9. Neurology. 2015. PMID: 26453645 Free PMC article. Clinical Trial.
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Kuhle J, et al. Among authors: pohl c. N Engl J Med. 2007 Jan 25;356(4):371-8. doi: 10.1056/NEJMoa063602. N Engl J Med. 2007. PMID: 17251533 Free article. Clinical Trial.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Kappos L, et al. Among authors: pohl c. Lancet Neurol. 2009 Nov;8(11):987-97. doi: 10.1016/S1474-4422(09)70237-6. Epub 2009 Sep 10. Lancet Neurol. 2009. PMID: 19748319 Free article. Clinical Trial.
Vitamin D as an early predictor of multiple sclerosis activity and progression.
Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C. Ascherio A, et al. Among authors: pohl c. JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993. JAMA Neurol. 2014. PMID: 24445558 Free PMC article.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C. Munger KL, et al. Among authors: pohl c. Ann Clin Transl Neurol. 2014 Aug;1(8):605-17. doi: 10.1002/acn3.91. Epub 2014 Aug 22. Ann Clin Transl Neurol. 2014. PMID: 25285313 Free PMC article.
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. Hartung HP, et al. Among authors: pohl c. J Neurol. 2015 Nov;262(11):2466-71. doi: 10.1007/s00415-015-7862-9. Epub 2015 Aug 5. J Neurol. 2015. PMID: 26239222 Free PMC article.
662 results